grant
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP)
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 15 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY2025AD dementiaAccountingActivities of Daily LivingActivities of everyday lifeAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimers DementiaAmyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis Motor Neuron DiseaseBindingBiologicalBiological MarkersBlindedBlood PlasmaBrainBrain DiseasesBrain DisordersBrain Nervous SystemCaringCausalityCessation of lifeChondroitin Sulfate ProteoglycanClinicalClinical TrialsCognitiveCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCollaborationsConduct Clinical TrialsDataDeathDecision MakingDegenerative Neurologic DisordersDepositDepositionDiagnosisDiagnostic testsDisease ProgressionDisturbance in cognitionDrug IndustryDrugsEncephalonEncephalon DiseasesEnglandEnrollmentEtiologyExperimental TherapiesFundingFutureGehrig's DiseaseGenerationsGenesGeneticGenetic predisposing factorGliaGlial CellsGoalsHereditaryImpaired cognitionIndividualInfrastructureInheritedInternationalIntracranial CNS DisordersIntracranial Central Nervous System DisordersInvestigational TherapiesInvestigational TreatmentsInvestigatorsKolliker's reticulumLipidsLiquid substanceLou Gehrig DiseaseMR ImagingMR TomographyMRIMRI biomarkerMRI markerMRIsMT-bound tauMagnetic Resonance ImagingMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMesencephalonMethodsMicro-tubuleMicrotubulesMid-brainMidbrainMidbrain structureMolecular InteractionNMR ImagingNMR TomographyNational Institutes of HealthNatural HistoryNerve CellsNerve UnitNervous System Degenerative DiseasesNeural CellNeural Degenerative DiseasesNeural degenerative DisordersNeurocyteNeurodegenerative DiseasesNeurodegenerative DisordersNeurogliaNeuroglial CellsNeurologic Degenerative ConditionsNeuronsNon-neuronal cellNonneuronal cellNorth AmericaNuclear Magnetic Resonance ImagingNucleic Acid Regulator RegionsNucleic Acid Regulatory SequencesOncologyOncology CancerOutcomeParalysis AgitansParkinsonParkinson DiseaseParticipantPatientsPharmaceutic IndustryPharmaceutical IndustryPharmaceutical PreparationsPhasePlacebo ControlPlacebosPlasmaPlasma SerumPreclinical dataPrimary ParkinsonismPrimary Senile Degenerative DementiaPrimary tauopathiesProgressive Supranuclear OphthalmoplegiaProgressive Supranuclear PalsyProteinsQOLQuality of lifeRandomizedRegulatory RegionsResearchResearch InfrastructureResearch PersonnelResearch ResourcesResearchersResourcesReticuloendothelial System, Serum, PlasmaRichardson syndromeSafetySeverity of illnessSham TreatmentSiteSteele-Richardson-Olszewski DiseaseSteele-Richardson-Olszewski SyndromeSymptomsTestingTherapeuticTimeUnited States National Institutes of HealthZeugmatographyabnormally aggregated tau proteinaging associated diseaseaging associated disordersaging related diseaseaging related disordersarmaxon growth cone guidanceaxon guidancebio-markersbiologicbiologic markerbiomarkerbiomarker discoverybrain atrophybrain volumecausationcerebral atrophyclinical trial protocolcognitive dysfunctioncognitive functioncognitive losscortical atrophydaily living functiondaily living functionalitydegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdesigndesigningdiagnostic biomarkerdiagnostic markerdiagnostic tooldisease associated with agingdisease causationdisease of agingdisease severitydisorder of agingdisorders associated with agingdisorders related to agingdrug developmentdrug/agenteffective therapyeffective treatmentefficacy trialenrollexperienceexperimental therapeutic agentsexperimental therapeuticsfilamentous tau inclusionfluidfunctional abilityfunctional capacitygenetic regulatory elementgenetic risk factorimpressioninclusion criteriainherited factorliquidlysosomal proteinsmagnetic resonance imaging biomarkermagnetic resonance imaging markermental statemental statusmicrotubule associated protein tau aggregationmicrotubule associated protein tau depositmicrotubule bound taumicrotubule-bound taumulti-modalitymultimodalitynerve cementneurodegenerative illnessneuronalneuroprotectionneuroprotectivenew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyopen labelopen label studypaired helical filament of taupharmacodynamic biomarkerpharmacodynamic markerplacebo controlledplacebo grouppreclinical findingspreclinical informationpreservationprimary degenerative dementiaprimary tau pathologyprogramsrandomisationrandomizationrandomly assignedrecruitresponsesafety testingsecondary end pointsecondary endpointself-aggregate tausenile dementia of the Alzheimer typesham groupsham therapytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttautau PHFtau Proteinstau accumulationtau aggregatetau aggregationtau factortau fibrillizationtau filamenttau neurofibrillary tangletau oligomertau paired helical filamenttau polymerizationtau-tau interactiontreatment effecttrial planningτ Proteinsτ aggregation
Description preview
PROJECT SUMMARY / ABSTRACT
Progressive Supranuclear Palsy (PSP) is a severe neurodegenerative disease of aging that usually leads to
death within 5-7 years of diagnosis. There are no effective treatments for PSP, but therapeutic approaches being
tested in clinical trials for other neurodegenerative diseases, such as Alzheimer’s (AD) and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click